228 related articles for article (PubMed ID: 25917632)
1. IL-11 signaling as a therapeutic target for cancer.
Putoczki TL; Ernst M
Immunotherapy; 2015; 7(4):441-53. PubMed ID: 25917632
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically.
Putoczki TL; Thiem S; Loving A; Busuttil RA; Wilson NJ; Ziegler PK; Nguyen PM; Preaudet A; Farid R; Edwards KM; Boglev Y; Luwor RB; Jarnicki A; Horst D; Boussioutas A; Heath JK; Sieber OM; Pleines I; Kile BT; Nash A; Greten FR; McKenzie BS; Ernst M
Cancer Cell; 2013 Aug; 24(2):257-71. PubMed ID: 23948300
[TBL] [Abstract][Full Text] [Related]
3. Emerging roles for IL-11 signaling in cancer development and progression: Focus on breast cancer.
Johnstone CN; Chand A; Putoczki TL; Ernst M
Cytokine Growth Factor Rev; 2015 Oct; 26(5):489-98. PubMed ID: 26209885
[TBL] [Abstract][Full Text] [Related]
4. IL-11: a prominent pro-tumorigenic member of the IL-6 family.
Grivennikov SI
Cancer Cell; 2013 Aug; 24(2):145-7. PubMed ID: 23948295
[TBL] [Abstract][Full Text] [Related]
5. Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11.
Metcalfe RD; Putoczki TL; Griffin MDW
Front Immunol; 2020; 11():1424. PubMed ID: 32765502
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 and interleukin-11: same same but different.
Garbers C; Scheller J
Biol Chem; 2013 Sep; 394(9):1145-61. PubMed ID: 23740659
[TBL] [Abstract][Full Text] [Related]
7. Pathologic consequences of STAT3 hyperactivation by IL-6 and IL-11 during hematopoiesis and lymphopoiesis.
Jenkins BJ; Roberts AW; Greenhill CJ; Najdovska M; Lundgren-May T; Robb L; Grail D; Ernst M
Blood; 2007 Mar; 109(6):2380-8. PubMed ID: 17082315
[TBL] [Abstract][Full Text] [Related]
8. More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer.
Putoczki T; Ernst M
J Leukoc Biol; 2010 Dec; 88(6):1109-17. PubMed ID: 20610798
[TBL] [Abstract][Full Text] [Related]
9. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.
Ernst M; Najdovska M; Grail D; Lundgren-May T; Buchert M; Tye H; Matthews VB; Armes J; Bhathal PS; Hughes NR; Marcusson EG; Karras JG; Na S; Sedgwick JD; Hertzog PJ; Jenkins BJ
J Clin Invest; 2008 May; 118(5):1727-38. PubMed ID: 18431520
[TBL] [Abstract][Full Text] [Related]
10. The role of proteolysis in interleukin-11 signaling.
Lokau J; Kespohl B; Kirschke S; Garbers C
Biochim Biophys Acta Mol Cell Res; 2022 Jan; 1869(1):119135. PubMed ID: 34624437
[TBL] [Abstract][Full Text] [Related]
11. STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease?
Nguyen PM; Putoczki TL; Ernst M
J Interferon Cytokine Res; 2015 May; 35(5):340-50. PubMed ID: 25760898
[TBL] [Abstract][Full Text] [Related]
12. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.
Taniguchi K; Karin M
Semin Immunol; 2014 Feb; 26(1):54-74. PubMed ID: 24552665
[TBL] [Abstract][Full Text] [Related]
13. Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression.
Jackson CB; Judd LM; Menheniott TR; Kronborg I; Dow C; Yeomans ND; Boussioutas A; Robb L; Giraud AS
J Pathol; 2007 Oct; 213(2):140-51. PubMed ID: 17724739
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice.
Tebbutt NC; Giraud AS; Inglese M; Jenkins B; Waring P; Clay FJ; Malki S; Alderman BM; Grail D; Hollande F; Heath JK; Ernst M
Nat Med; 2002 Oct; 8(10):1089-97. PubMed ID: 12219085
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways: IL11 as a tumor-promoting cytokine-translational implications for cancers.
Ernst M; Putoczki TL
Clin Cancer Res; 2014 Nov; 20(22):5579-88. PubMed ID: 25074610
[TBL] [Abstract][Full Text] [Related]
16. Repurposing the selective estrogen receptor modulator
Thilakasiri P; Huynh J; Poh AR; Tan CW; Nero TL; Tran K; Parslow AC; Afshar-Sterle S; Baloyan D; Hannan NJ; Buchert M; Scott AM; Griffin MD; Hollande F; Parker MW; Putoczki TL; Ernst M; Chand AL
EMBO Mol Med; 2019 Apr; 11(4):. PubMed ID: 30885958
[TBL] [Abstract][Full Text] [Related]
17. Soluble gp130 prevents interleukin-6 and interleukin-11 cluster signaling but not intracellular autocrine responses.
Lamertz L; Rummel F; Polz R; Baran P; Hansen S; Waetzig GH; Moll JM; Floss DM; Scheller J
Sci Signal; 2018 Oct; 11(550):. PubMed ID: 30279168
[TBL] [Abstract][Full Text] [Related]
18. A panoramic review and in silico analysis of IL-11 structure and function.
Negahdaripour M; Nezafat N; Ghasemi Y
Cytokine Growth Factor Rev; 2016 Dec; 32():41-61. PubMed ID: 27312790
[TBL] [Abstract][Full Text] [Related]
19. The role of IL-15 in gastrointestinal diseases: a bridge between innate and adaptive immune response.
Pagliari D; Cianci R; Frosali S; Landolfi R; Cammarota G; Newton EE; Pandolfi F
Cytokine Growth Factor Rev; 2013 Oct; 24(5):455-66. PubMed ID: 23791986
[TBL] [Abstract][Full Text] [Related]
20. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential.
Entezari AA; Snook AE; Waldman SA
Expert Opin Ther Targets; 2021 May; 25(5):335-346. PubMed ID: 34056991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
